Return to News

COSMIC News

COSMIC_actionability_logo_1.png

COSMIC Actionability: Release v93 (March 2021)!

24 Mar 2021

Actionability release graphic noCTA.png

We are proud to announce after three years of high quality manual curation from PhD level experts, our latest product in the COSMIC suite, Mutation Actionability in Precision Oncology (Actionability), has launched.

At COSMIC we pride ourselves on 50+ person years of high quality manually curated data by PhD level experts which allows researchers to understand the genetics that drive cancer, which are the genes and mutations that matter and finally, seek to understand what can be done about them.

The Actionability journey started in 2018 when we sought to provide a resource that addresses the question “What treatment options are available or under investigation for cancer patients with somatic mutations?”, adding another piece to the puzzle of precision oncology.

The aim of COSMIC Actionability is to indicate the availability of drugs that target mutations in cancer and track the progress of clinical studies towards making new drugs available. Drugs that target somatic mutations are represented at all stages of drug development, through safety and clinical phases to market and repurposing, with additional case studies. Primarily the data comes from clinical trials databases, however our manual curation efforts add up to 3x more data than using clinical trials alone*.

The principal units of actionability are mutation, disease, and drug. Capturing relations between these units allows identification of existing and upcoming drugs that target particular genetic variants in specific cancer types.

In our first release of Actionability (v93), the data includes well-known genes such as EGFR and KRAS but also other genes such as EZH2 for its topical scientific relevance. We have curated point mutations, fusions and other mutations.

KEY ACTIONABILITY STATS - v93, Mar 2021.png

















A full list of gene coverage can be found in the Actionability about page.

Our release cycle will follow that of COSMIC, three times per year. At every release, we aim to update the existing records to ensure that the results are up to date whilst adding curating additional data.

We have been thrilled at the responses to our request for feedback on the pre-release sample data file and the interactive prototype of the website. We are responding to your feedback. Future versions of Actionability will extend mutation mapping and have closer integration with other COSMIC tools. We’d love to hear your feedback and if you have any thoughts for the future direction of Actionability, please contact us via cosmicengagement@sanger.ac.uk.

The Actionability data is available as a download file containing the entire actionability dataset, from the COSMIC downloads page. More information can be found on the Actionability about and help documentation pages.

For academic use, the data is freely available. For commercial use of the data, a license fee may apply, to find out more please contact our commercial distribution partner, Qiagen via bioinformaticssales@qiagen.com.

*Calculation can be found in FAQs.


Keep up date to with COSMIC

Please follow us on LinkedIn, Twitter, Facebook and via our email announcements to keep abreast of the latest COSMIC news and developments. If you do not receive our emails, please update your email preferences, as shown below, in your COSMIC account.

Email preferences graphic.jpg

About

COSMIC, the Catalogue Of Somatic Mutations In Cancer, is the most comprehensive resource for exploring the impact of somatic mutations in human cancer. Here on our news page we aim to give you an insight into what we are doing and why. We will keep you updated with new developments and release information as well as any events we are hosting.

Tags

release

workshop

website

curation

COSMIC-3D

vacancies

downloads

user experience

data submission

website update

Cancer Gene Census

mutation ID

Hallmarks of Cancer

GRCh37

drug resistance

GRCh38

video

tutorial

birthday

International Women's Day

literature

mutational signatures

Mesothelioma

conference

AACR

gene

Bile duct cancer

cholangiocarcinoma

Europe PMC

Service announcement

blog

survey

updates

v90

search

cosv

updated

CDS

Fasta

cDNA

disease focus

world cancer day

new product

cmc

DIAS

Actionability

COSMIC

webinar

introduction to cosmic

mutations

celebrating success

Oncology

oncology trials

precision medicine

clinical trials

precision oncology

cancer

genomics

immuno oncology

breast cancer

cosmic v95

bioinformatics

cancermutationcensus

COSMICv95

Lung Cancer

Glioblastoma

testicular cancer

cancer prevention

biomarkers

Cancer Research

tumour microenvironment

copy number variants

ageing

genes

genome

clones

smoking

Clonal haematopoesis

tumour

inherited

disease

individuals

risk

variants

leukaemia

Myelodysplastic syndrome

lymphoma

haematological cancers

Myeoloproliferative neoplasms

myeloma

haematological

somatic mutations

blood cancers

blood cancer

NRAS

acral lentiginous melanoma

BRAF

melanoma

driver gene

skin cancer

uv light

Mexico

chromosome

acral melanoma

breed predisposition

genetics

PIK3CA

driver genes

canine cancer

data ecosystem

database

canine

tumour board

barrett's oesophagus

oesophageal cancer

upper gi

gene panel

cell lines project

Wellcome Sanger Institute

sanger

uv radiation

uv nail lamp

SBS18

reactive oxygen species

DNA damage

uv damage

sebaceous gland carcinoma

Kaposi cell carcinoma

Lynch syndorme

carcinoma

cancerresearch

Merkel cell carcinoma

Muir-torres syndrome

MLH1

sanger institute

Mike Stratton

cancer genome project

BRCA2

mutographs

resistance mutations

IWD24

Women in STEM

IT

computational biology

STEM career

computer science

v100

cancer mutation census

genetic oncology

#genomics

#high medical need

#genetics

#cancer mutation census

#cancer gene census

#whole genome sequencing

#oncology

#whole exome sequencing

#cosmic

#somatic mutation

#thyroid cancer

NGS panel